PMD129 When Is A Bone Fracture No Longer “Fresh”?  by Scott, RA et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A367
the Committee for technologies that ultimately did not receive positive endorse-
ment due to clinical benefit or cost considerations. ConClusions: The MTEP is 
the most commonly used process to assess routed technologies and the major-
ity of MTEP evaluations have resulted in positive endorsement. The MTEP process 
assigns equal prominence to healthcare system and patient benefits, with decisions 
being based on the full body evidence available for a technology. However, where 
evidence of clinical effectiveness was associated with uncertainty, the influence of 
demonstrated healthcare system benefits appeared to have limited effect on final 
decision-making.
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objeCtives: To describe the use of self-monitoring of blood glucose (SMBG) in a 
cohort of newly treated T2DM subjects and to assess the contribution of SMBG on 
overall antidiabetic and cardiovascular disease prescription costs. Methods: A 
population based retrospective cohort study was conducted using the Irish national 
pharmacy claims database. Newly treated T2DM patients were identified for 2012 
as being initiated on oral antidiabetic monotherapy and having received no anti-
diabetic therapy in the previous year. Subjects were followed for one year post 
treatment initiation. The association between prescription costs and SMBG was 
assessed using generalised linear model with gamma family and log link functions 
to handle the right skew of the data adjusting for various demographic and treat-
ment factors. Cost ratios and 95% CIs were obtained from this analysis and were 
used to determine the contribution of SMBG to prescription costs. Results: A total 
of 12,941subjects were eligible for the study with 64% of subjects using SMBG. SMBG 
use was highest in subjects aged 40-49 years (71%) and decreased with age, with 
48% of subjects aged 80-89 years using SMBG. Most subjects used SMBG greater than 
once a week but less than daily (41%) or daily and more frequently (51%). Use of 
SMBG resulted in dispensing costs that were overall 81% higher than those without 
SMBG use (95% CI 1.76, 1.92). ConClusions: Use of SMBG in newly treated T2DM 
was high including the frequency of use and resulted in high associated costs. 
SMBG represents a significant financial component in diabetes care, yet previous 
work has shown no clear benefit in newly treated type 2 diabetes patients on oral 
therapy. There is the potential for cost savings by introducing a review or limit on 
the amount of SMBG tests available to newly treated T2DM patients.
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objeCtives: The objective of this research is to provide an overview of the regu-
latory process of medical devices market access in Egypt and Saudi Arabia. The 
research paper identifies regulatory institutions, processes, and policy framework 
of the national medical devices policy agenda of Egypt and Saudi Arabia respec-
tively. Methods: A systematic search of the literature for medical device regula-
tory information was performed, in academic journals and in relevant regulatory 
authorities’ data sources (Egyptian Drug Authority and Saudi FDA web portals). The 
following databases were searched: PubMed (Medline), Science Direct (EMBASE), 
Scopus and the Arabic database Al Manhal. The search methodology employed was 
in line with PRISMA guidelines. The search language was limited to English and 
Arabic. Results: In total, 41 records were included in the qualitative synthesis 
of this review. The governance, process and implementation of medical devices 
market access have been analyzed in detail. The policy framework of both countries 
is adopted from the International Medical Device Regulatory forum and certain 
reference countries. Concerning products’ technical requirements, direct testing 
of medical devices is not required. However, documentary evidence of a medical 
device’s authorization to be sold in a reference country is mandatory. Challenges 
are related to the interim nature of medical devices legislation in both countries, 
presence of a considerable degree of corruption. In addition there is a lack of trans-
parency and electronic databases, especially in Egypt. ConClusions: In both Saudi 
Arabia and Egypt, medical devices market access is straightforward if there is proof 
of authorization to sell a product in a reference country. However, this system has 
disadvantages in terms of safeguarding patient safety and enabling fast access of 
innovations. Lack of transparency, incomplete regulations, corruption, and a lack of 
comprehensive policy for medical devices are challenges faced by both countries.
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objeCtives: Hospital acquired infections (HAIs) can have a serious impact on 
both clinical and economic outcomes. As a result, hospitals implement infec-
tion control (IC) policies to prevent and reduce the transmission of HAIs includ-
ing various approaches to screening and testing incoming or admitted patients. 
Early identification of HAIs is key to limiting their clinical and economic impact. 
Molecular diagnostics (MDx) have the potential to improve IC strategies by quickly 
and accurately identifying patients with suspected or confirmed infections. To 
increase adoption of this technology, both MDx manufacturers and hospital qual-
ity stakeholders have expressed interest in value-based contracting for HAI tests. 
eligibility, order, delivery and invoicing) in an integrated manner in order to easily 
activate new market opportunities from the perspective of Companies, Payers and 
Patients. By defining appropriate minimum datasets, it is possible to involve all 
stakeholders obtaining systematic, homogeneous and high-quality real-world data 
on the use and appropriateness of such devices. ConClusions: The introduction of 
online integrated and shared infrastructures allows to activate common processes 
among Payers and Companies in the challenge of introducing innovative therapies 
and devices in a strained macroeconomic scenario, with the aim to simplify market 
access, facilitate transparency, monitor related costs, while enabling the collection 
of Healthcare Big Data for scientific purposes.
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objeCtives: Affixing a CE mark to a product means that the manufacturer is 
declaring that the product meets all legal requirements as well as conforming 
to relevant product safety directives in the EU. CE marking is mandatory, but 
only applies to products that are covered by the subject matter of one or more 
of the New Approach Directives. We aim to clarify the process for obtaining a CE 
mark. Methods: Published reviews, our experience and government and industry 
records were used to outline the complexities of this process, including how to 
determine the relevant type of classification and the steps that need to be taken to 
gain a CE Mark. Results: Medical devices fall into three categories, each of which 
are governed by a different EU directive: Directive of Active Implantable Medical 
Devices (90/385/EEC), Medical Devices Directive (93/42/EEC), and Directive of in Vitro 
Diagnostic Medical Devices (98/79/EC). Each one will encompass guidelines relating 
to an individual product and whether it is required to bear a CE mark. Once a CE 
Mark has been obtained a ‘declaration of conformity’ must be signed before you 
can place the CE mark on your product. This states that the manufacturer takes 
sole responsibility for the conformity within all the legal requirements to achieve 
a CE mark. CE marking means that the product can be marketed anywhere in the 
EU. ConClusions: A CE mark states that a product has been assessed before being 
placed on the market and satisfies legislative requirements of the applicable EC 
directives. It ensures that a product has ‘free-movement’ within the EU as well as 
permitting the ‘withdrawal of products’, which do not conform. More and more 
products are required to have a CE mark if they want to gain access to EU market.
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objeCtives: Robust literature demonstrates the clinical value of low-intensity 
pulsed ultrasound (LIPUS) in the treatment of fresh bone fractures. However, each 
published study used an arbitrary time post-fracture to define a “fresh fracture” for 
study inclusion. In the absence of an accepted clinical definition of fresh fracture, 
many third-party payers have adopted study inclusion criteria as de facto defini-
tions of fresh fracture. Yet exclusion of older fractures may deny access to patients 
who could benefit from LIPUS. We pooled data from patients in a post-market LIPUS 
registry required by the Food & Drug Administration to analyze the inflection point 
at which fracture heal rates begin to decline. Methods: Patients are evaluated if the 
following data are known: days to LIPUS treatment; days on LIPUS treatment; and 
outcome of treatment (Heal / Fail). We present data from 7,117 patients treated with 
LIPUS within 365 days of fracture. We plot (Heal rate) vs. (Days to LIPUS treatment), 
to determine the inflection point at which Heal rate begins to decline. Results: 
Heal rate (Number of patients healed / Number of patients treated) did not differ 
significantly or clinically for at least 10 weeks following fracture. In 284 fracture 
patients who began LIPUS within 1 week of fracture, the heal rate was 97.2% (276 
healed / 284 treated). In 246 patients who began LIPUS treatment 10 weeks after 
fracture, the heal rate was 97.6% (240 healed / 246 treated). There may be a decrease 
in heal rate after 10 weeks, but the heal rate for patients at week 12 was 95.6% (195 
healed / 204 treated). ConClusions: Heal rate with LIPUS was ~97% for ≤ 10 weeks 
following fracture. Many patients who could benefit may be unnecessarily excluded 
from treatment by payer guidelines. We will evaluate heal rate bone-by-bone (tibia, 
femur, humerus, radius, metatarsal) using this method.
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objeCtives: Firstly, to identify what proportion of medical technologies notified to 
the National Institute for Health and Care Excellence’s (NICE) Medical Technologies 
Appraisal Committee (MTAC) are selected for evaluation by the MTEP. Secondly, to 
analyse the MTEP Committee’s interpretation of claimed healthcare system benefits 
and identify the influence of these benefits on decision-making. Methods: The 
NICE website was used to identify: technologies considered by the MTAC up to May 
2015; the routing information for each technology; the healthcare system benefit 
claims and decision data for all technologies routed to the MTEP. The healthcare 
system benefit claims were categorised according to criteria listed in the NICE MTEP 
methods guide to facilitate identification of any association between the type of 
benefit claimed and the decision outcome. The decision-making committee’s con-
clusions on the claimed healthcare system benefits were interpreted. Results: 
By May 2015, the MTAC at NICE had considered 157 products, of which 99 were not 
selected for evaluation. Of the 58 products selected for evaluation, 35 were routed to 
the MTEP. Seventy-one per cent of MTEP decisions endorsed technology adoption. 
There have been instances of claimed health system benefits being accepted by 
